Agilent Technologies this week launched the Agilent Complex Proteomics Standard for the validation of mass spectrometry-based workflows for protein identification.
Targeted for protein biomarker discovery work, the standard was developed in collaboration with Ruedi Aebersold a professor of molecular systems biology at the Federal Technical University in Zurich and the University of Zurich, and John Yates at the Scripps Research Institute. According to Agilent its standard is the only one "able to mimic the complexity and diversity of a typical proteomic sample," and can be used to benchmark different proteomic workflows and validate them over time and across multiple instruments and laboratories.
The standard contains more than 1,500 proteins covering a wide range of protein sizes and molecular weights, isoelectric point, and hydrophobicity. Genetic distance between Pyrococcus furiosus and human or other organisms typically used in proteomic experiments helps avoid erroneous protein identifications, Agilent said in a statement.
The standard can be used on a wide range of LC-MS-based applications and with the Agilent 1200 series LC and 6000 series mass specs and other mass specs from other vendors, the company said.
Bio-Rad Laboratories and Bruker this week launched the Lucid Proteomics System.
The platform combines Bio-Rad's SELDI-based array technology with Bruker's ultrafleXtreme MALD-TOF/TOF instrument, allowing researchers to do both top-down and bottom-up profiling of proteins on the same system [See PM 06/11/09].
The system comprises the Lucid profiling access pack, which includes array holders, system license, software, system qualification kit, ProteinChip arrays, buffers, and accessories needed to do ELDI-based protein profiling; the Lucid ID access pack, which includes an array holder, system license, consumables, protocols, and guidelines for performing protein and peptide identifications; and the ultrafleXtreme MALDI-TOF/TOF mass spec configured for ProteinChip SELDI products.
Pressure BioSciences this week launched the ProteoSolve-CE Native and ProteoSolve-CE Stringent kits for extracting proteins from C. elegans.
The kits are dependent of the company's pressure cycling technology, and intended for use on its PCT Sample Preparation System. The kits contain proprietary reagents and Pressure BioSciences' Pulse consumable processing containers.
The kits allow researchers to extract an abundance of either native or denatured proteins from "nearly all parts of the C. elegans organism," PBS said in a statement.
Thermo Fischer Scientific launched the Pierce Human In Vitro Glycoprotein Expression kit and the Pierce Human In Vitro Protein Expression kit this week.
The glycoprotein kit improves post-translation modification of proteins by "synthesizing and accurately glycosylating proteins at much higher efficiencies than competing commercial methods," Thermo Fisher said in a statement. When glycosylation is not necessary, the In Vitro Protein Expression kit may be used.
Phenomenex this week introduced the KrudKatcher Ultra column protector.
The KrudKatcher Ultra is rated up to 20,000 psi making it compatible with the highest pressure UHPLC columns and Phenomenex's Kinetex core-shell line, Phenomenex said in a statement.
The KrudKatcher Ultra filters and removes microparticulates from the LC flow stream, protecting the column and ensuring longer product life.
Kinaxo Biotechnologies this week launched the KinAffinity services for the profiling of kinase inhibitors in cells or tissues.
According to the German firm, KinAffinity determines affinities for native kinases expressed within a cellular proteome "and thus overcomes the limitations of traditional biochemical assays that use only recombinant proteins."
KinAffinity uses proprietary chemical proteomics methods with quantitative mass spectrometry. Endogenously expressed, post-translationally modified kinases are enriched by a ready-to-use affinity matrix in the presence of native binding partners and "competed with the kinase inhibitor of interest," Kinaxo said in a statement. "Subsequently, bioinformatics methods are used to reveal the inhibitor's quantitative cellular target profile." The inhibitors targets are ranked by their affinities.
KinAffinity can be applied to both type l and type ll kinase inhibitors, the company said.